Genelytica Sp. z o.o
Genelytica Sp. z o.o is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
Multicentre Evaluation of Clinical Applications of Innovative PET/MRI with a 68Ga-PSMA-11 Radiotracer when Planning a Personalised Therapy in Prostate Cancer Patients
Sponsor Medical University Of Bialystok
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The absence of a uniform histopathological reference standard for all detected lesions prevented reliable estimation of absolute sensitivity and specificity and introduced potential partial-verification bias.
- Site heterogeneity in multidisciplinary-team decision-making was a limitation; the Bydgoszcz site was excluded from final analysis because of its homogeneous patient population, with sensitivity analyses not changing the conclusions.
- Protocol deviations and missing data for selected variables, including radiation dose, were reported limitations.
These findings describe the trial, not the service provider’s performance or responsibility.
Tandem therapy LutaPol/ltraPol ( I 77Lu / 90Y-DOTATATE) as an effective method in the treatment of neuroendocrine neoplasmas.
Sponsor Narodowe Centrum Badan Jadrowych
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
An open-label phase 2/3 study to analyse the feasibility and evaluate the safety of intravenous administration of 99mTc-PSMA-T4 in patients with prostate cancer
Sponsor Narodowe Centrum Badan Jadrowych
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Genelytica Sp. z o.o?
The 2026-10-09 snapshot links Genelytica Sp. z o.o to 3 distinct CTIS trials. Recorded services include Clinical monitoring, Data management, Project management, Electronic data capture, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Genelytica Sp. z o.o?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Urology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Genelytica Sp. z o.o conducted?
The linked trials record locations in 1 country, including Poland. These are trial locations, not confirmed office locations or countries where Genelytica Sp. z o.o delivered services.
What can this page tell me about Genelytica Sp. z o.o's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Genelytica Sp. z o.o. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Genelytica Sp. z o.o.